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Introduction: Persistent infections with human papillomavirus (HPV) are a necessary cause of cervical cancer and
are responsible for important morbidity in men and women. Since 2007, HPV vaccination has been recommended
and funded for all girls aged 12 to 17 in Germany. A previously published cost-effectiveness analysis, using a static
model, showed that a quadrivalent HPV vaccination programme for 12-year-old girls in Germany would be cost
effective. Here we present the results from a dynamic transmission model that can be used to evaluate the impact
and cost-effectiveness of different vaccination schemas.
Methods: We adapted a HPV dynamic transmission model, which has been used in other countries, to the German
context. The model was used to compare a cervical cancer screening only strategy with a strategy of combining
vaccination of females aged 12–17 years old and cervical cancer screening, based on the current recommendations
in Germany. In addition, the impact of increasing vaccination coverage in this cohort of females aged 12–17 years
old was evaluated in sensitivity analysis.
Results: The results from this analysis show that the current quadrivalent HPV vaccination programme of females
ages 12 to 17 in Germany is cost-effective with an ICER of 5,525€/QALY (quality adjusted life year). The incremental
cost-effectiveness ratio (ICER) increased to 10,293€/QALY when the vaccine effects on HPV6/11 diseases were
excluded. At steady state, the model predicted that vaccinating girls aged 12 to 17 could reduce the number of
HPV 6/11/16/18-related cervical cancers by 65% and genital warts among women and men by 70% and 48%,
respectively. The impact on HPV-related disease incidence and costs avoided would occur relatively soon after
initiating the vaccine programme, with much of the early impact being due to the prevention of HPV6/11-related
genital warts.
Conclusions: These results show that the current quadrivalent HPV vaccination and cervical cancer screening
programmes in Germany will substantially reduce the incidence of cervical cancer, cervical intraepithelial neoplasia
(CIN) and genital warts. The evaluated vaccination strategies were all found to be cost-effective. Future analyses
should include more HPV-related diseases.
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Persistent infections with human papillomavirus (HPV)
are a necessary cause of cervical cancer and are respon-
sible for important morbidity in both men and women
[1,2]. HPV are classified as high or low risk, based on
their oncogenic potential. In Europe, high risk types
HPV16 and HPV18 are responsible for 75% of cervical
cancers, 60% of high-grade cervical intraepithelial neo-
plasia (CIN2/3) and 25% of low-grade cervical intra-
epithelial neoplasia (CIN1) [3,4]. Low risk types HPV6
and HPV11 are responsible for about 10% CIN1 and
90% of genital warts [5]. HPV are also responsible for
some other anogenital cancers (vulvar, vaginal, anal and
penile) and some head and neck cancers [6-8].
In Germany, it is estimated that there are nearly
5,500 new cases of cervical cancer and 1,500 cervical
cancer deaths every year [9,10]. The EU-standardized
incidence and mortality rates were estimated to be
11/100,000 and 2.5/100,000 women in 2006 [9]. Genital
warts are frequent; the estimated incidence is 169.5/
100,000 person-years for the German population aged
10 to 79 [11]. The peak incidence occurs in females at
20 to 24 years (627/100,000 person-years) and in males
at 25 to 29 years (457/100,000 person-years) [11].
Cervical cancer is one of the target cancers covered
by the statutory German cancer screening programme.
All German women are eligible to receive an annual cer-
vical examination including a Papanicolaou (Pap) smear,
beginning at 20 years old. The annual uptake has been
estimated to be about 50% of the eligible population [12].
Since 2007, HPV vaccination has been recommended
and funded for all girls aged 12 to 17 in Germany [13].
Two prophylactic vaccines are currently available. One
is a quadrivalent HPV6/11/16/18 vaccine, licenced for
the prevention of premalignant genital lesions (cervical,
vulvar and vaginal), cervical cancer and external genital
warts [14]. The other vaccine is a bivalent HPV16/18
vaccine, licenced for the prevention of premalignant cer-
vical lesions and cervical cancer [15]. In addition, the
results from a randomised controlled trial in men
demonstrated the efficacy of the quadrivalent HPV vac-
cine against external genital lesions in men, including
genital warts and anal precancerous lesions [16,17].
A previously published cost-effectiveness analysis, using
a static model, showed that a quadrivalent HPV vaccin-
ation programme for 12-year-old girls in Germany would
be cost effective, with an incremental cost-effectiveness
ratio (ICER) of 10,530€/QALY (quality-adjusted life year)
[18]. However, this static model cannot take into consid-
eration changes in HPV infection rate over time and it
did not adequately reflect the current recommendation
in Germany to vaccinate 12 to 17-year-old-girls. Dynamic
transmission models, unlike static models, can be used to
evaluate the epidemiological impact and cost-effectivenessof different vaccination schemas, taking into account
both direct (for those vaccinated) and indirect effects (in
those not vaccinated: herd immunity effect). This model-
ling approach will be useful for healthcare decision
makers in estimating the expected benefits from the
vaccination programme that has been implemented in
Germany. In this paper we report the results from the
adaptation of a previously published [19] dynamic trans-
mission model to assess the health and economics
impact of the quadrivalent HPV vaccine in Germany
from a third-party payer perspective.
Methods
Dynamic transmission model
We adapted a HPV dynamic transmission model that
has already been used in the United States (US), United
Kingdom (UK), Mexico and Norway to the German
context [19-22]. The details of the model structure and
the equations have been published previously and are
outlined in Figure 1 [21,23]. In summary, this model
simulates the spread of HPV 6/11/16/18 infection and
diseases (CIN, cervical cancer, genital warts) in an age-
structured population. The demographic portion of the
model defines the characteristics of the simulated popu-
lation and describes how people enter, age and exit
the model. The epidemiological portion of the model
simulates HPV transmission and infection as well as the
development of the HPV related diseases in the sexually-
active population of females and males.
The model outcome parameters were driven by five
categories of input parameters: demographic data; sexual
behaviour; cervical cancer screening; natural history; and
treatment patterns.
Adaptation process
There were three steps in the adaptation process:
1. Assessment of the transferability of the model
structure to the German setting
2. Review of the input parameters to fit the German
setting
3. Manual calibration of the model to fit the
epidemiology data observed in Germany
Transferability of the model structure
There is no evidence that the course of disease, from
HPV infection passing through the various disease stages
up to cervical cancer death, is different in Germany from
that in the US or any other country. The original model
also considers treatment probabilities instead of explicit
treatment strategies. This makes the model easily trans-
ferable to other countries. Furthermore, the screening
module in the original model is based on yearly routine
cervical cancer screening for women over 20 years old
Table 1 Cervical cancer screening parameters (based on
[10,27])
Parameter Parameter estimate (%)
% of women not regularly screened 40


















Figure 1 Schematic representation of the dynamic transmission model CIN: cervical intraepithelial neoplasia.
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Germany [24]. Thus, we concluded that the model struc-
ture is transferable to the German situation.
Model input parameters
A literature search was undertaken to identify German-
specific values for the input parameters; this search was
supplemented by advice from experts and cancer registry
analyses, when necessary.
Demographic data and sexual behaviour patterns
The demographic data was obtained from the German
federal statistical office; the total population aged 12 and
over in Germany on 31 December 2008 was estimated
to be 73 234 448 people [25]. No German-specific data
were identified for the sexual behaviour patterns. Since
the data in the literature suggested that the sexual
behaviour patterns are similar to those in the UK, so
these data from the UK were integrated into the model
(Additional file 1: Table S1) [26].
Cervical cancer screening and vaccination strategies
The annual cervical cancer screening rates and the sen-
sitivity and specificity of Pap smear tests and colposcopy
were based on data from a German health technology
assessment report (Table 1) [10].
Based on clinical trial data, the prophylactic efficacy of
the quadrivalent HPV vaccine for preventing incident
HPV 6/11/16/18 infections was assumed to be 90% [28].
We assumed the efficacy of the quadrivalent HPV vaccine
for preventing HPV 6/11/16/18-related CIN, cervical can-
cer and genital warts was 95.2%, 100% and 98.9% respect-
ively [28]. Additionally, the model included the fact thatthe quadrivalent HPV vaccine would not protect against
HPV disease present at the time of vaccination and that it
would not affect the rate of clearance and infectiousness of
‘breakthrough’ cases [19]. In line with other models, we
assumed in the base case that the quadrivalent HPV vac-
cine provided life-long protection [21,29].





Annual vaccination coverage rates
(base case scenario, %)














1 20 27 38 NA NA NA
2 14 28 33 NA NA NA
3 8 9 16 NA NA NA
4 8 11 6 NA NA NA
5 11 13 6 NA NA NA
6 12 14 7 NA NA NA
7 13 15 8 15 20 12
8 14 16 9 20 25 18
9 15 17 10 30 25 20
10 16 19 11 40 30 25
11+ 16 19 11 45 30 25
NA: Not Applicable.
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screening only strategy with a strategy of combining
vaccination of females aged 12–17 years old and cer-
vical cancer screening, based on the current recommen-
dations in Germany. The vaccination coverage rates
were set to reflect the current situation in Germany for
the first years of vaccination. In the base case, annual
rates by age were set to reach a total cumulative cover-
age rate of 45% and 55% for the 12–14 and 15–17 re-
spectively (Table 2). In addition, the impact of
increasing vaccination coverage in this cohort of females
aged 12–17 years old was evaluated in sensitivity ana-
lyses (Table 2).
Disease and treatment patterns
Natural history parameters were based on international
data and were the same as in the original model [23].
Cervical cancer mortality rates by stage (local, regional,
distant) and age were not publicly available for the
whole of Germany as there is no central cancer registry.
Therefore we used data from the Bavarian Cancer
Registry and modified it to account for the difference in
the cancer death rate between Bavaria and all of
Germany (Additional file 1: Table S2) [32]. The cervical
cancer mortality rates in Bavaria (world standardised
rate of 1.6 per 100,000 women) are lower than expected
for the whole of Germany (world standardised rate of
1.8 per 100,000 women) [30]. We, therefore, adjusted
the data from Bavaria by 12.5% to reflect the estimated
national rate.
The percentages of women treated for CIN/carcinoma
in situ (CIS) and genital warts were based on German
cost studies (Additional file 1: Table S3) [31]. Thepercentage of women, by age group, who undergo hys-
terectomy annually, was based on data from a German
database (Additional file 1: Table S4) [24].
Economic parameters
The costs for the diagnosis and treatment of HPV-
related diseases were based on German cost studies and
a German health technology assessment report (Table 3)
[18,31]. The cost for three doses of vaccine and adminis-
tration was set at €451.20 (Table 3).
The health utility values for the disease (Table 3) and
German general population (Additional file 1: Table S5)
health states were based on published data [33,34].
Model validation
The predictive validity of the model was assessed by
comparing predictions from the model with available
epidemiological data on incidence and mortality of cer-
vical cancer and genital warts in Germany [11,30]. The
epidemiologic data for genital warts, cervical cancer
and cervical cancer deaths in Germany was adjusted
by the percentage estimated to be HPV6/11/16/18-
related (Table 4) [3,5]. A target window of ±10% was
set to define how well all the calibration targets fitted.
The model was calibrated to ensure that predicted
values were consistent with the expected epidemio-
logical data for Germany. We did not modify the nat-
ural history parameters values used in the original US
model as they were the results from an extensive cali-
bration process and they are not expected to change
between countries [21]. Calibration involved only a few
parameters that were based on either imprecise or
assumed data that are responsible for reduced reliability:















Local cervical cancer 7,523.00 0.76
Regional cervical cancer 15,649.00 0.67
Distant cervical cancer 17,152.00 0.48




Vaccination (3 doses and
administration)
451.20 -
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ing rates, the proportion of women not regularly
screened and cervical cancer mortality rates. Values fi-
nally used (presented in Table 1 and Additional Tables)
were still considered as realistic for the German setting.
We adjusted the model to obtain the target corridor se-
quentially to minimize the interdependency of the
modified parameters: First, we adjusted for the annual
number of genital warts, then the annual number of
cervical cancer cases, followed by the annual number of
cervical cancer deaths. This order was chosen because
genital warts are considered to be independent of the
other two parameters and cervical cancer incidence and
cervical cancer deaths are correlated.Table 4 Calibration targets for genital warts (in females



















95,119 - 116,257 3,751 -
4,585
1023 - 1,251
* HPV6/11 for genital warts [5]; HPV 16/18 for cervical cancer cases and deaths
[3,9,11].Model analyses
The analyses were done from a third-party payer per-
spective, over a lifetime horizon. The discount rate on
all costs and benefits was set at 3%. The model was used
to assess the impact of HPV 6/11/16/18 vaccination on
the burden of HPV 6/11/16/18-related diseases (cervical
cancer and genital warts) in both males and females.
The potential cross-protection effect of the vaccine
against HPV types not included in the vaccine was not
evaluated as these types are included in the model.
The model also provided an estimation of the quality-
adjusted life years (QALYs), total costs and the incre-
mental cost-effectiveness ratio (ICER).
Univariate sensitivity analyses were performed to iden-
tify which of the following parameters influenced the
results most strongly:
1 Vaccine duration of protection (20 years)
2 Disease management costs (by +/− 20%);
3 Disease utility scores (+/− 20% and cancer survivor
utility set to 1)
4 Discount rates at 0% and 5%;
5 No prevention of HPV6/11 diseases;
6 Increased vaccine coverage for women aged
12–17 years (table 2)
Results
Results of the validation process
The calibrated model predicted, with current screening
practices and in the absence of vaccination, an annual
number of 104,852 cases of HPV6/11 related genital
warts in both males and females (target: 95,119 to
116,257); 4,507 cases of HPV16/18 related cervical
cancer (target: 3,751 to 4,585) and 1,101 cervical cancer
deaths (target: 1,023 to 1,251) (Table 4). Therefore, the
predictions from the model fitted observed epidemio-
logical data in Germany.
Epidemiological impact of HPV6/11/16/18 vaccination
in Germany
The annual number of HPV6/11/16/18 events prevented
with vaccination at different time frames are summarised
in Table 5. Figure 2 shows the impact of vaccination
over time on the incidence of HPV16/18 related cervical
cancer cases. The decrease in the incidence of cervical
cancer would be continuous and stabilise at approxi-
mately 1500 cases per year (65% reduction) at about
80 years after the start of the vaccination programme.
After 25 years from the start of the programme, a 21%
reduction in the incidence of cervical cancer would be
seen. The impact of increasing vaccination coverage in
this age group would lead to earlier reductions and
result in a plateau after about 80 years at about 600 cases
of cervical cancer cases annually, which is a reduction of
Table 5 Annual number of HPV 6/11/16/18 events
prevented by quadrivalent HPV vaccination of 12 to
17 year old girls in Germany and screening, compared
with screening alone
Annual number of disease events prevented
Time since start of vaccination programme
(years)
5 15 25 50 100
Cervical cancer 5 298 953 2,474 2,955
Cervical cancer deaths 0 21 135 559 720
CIN 2/3 1,711 9,288 12,694 14,899 15,429
CIN 1 899 3,552 4,366 4,751 4,829
Genital warts
female 16,350 30,780 33,001 35,075 36,049
male 13,874 26,999 27,172 25,948 25,691
Total 30,225 57,779 60,173 61,023 61,740
HPV 16/18 events 2,322 12,134 16,876 20,906 21,966
HPV 6/11 events 30,518 58,783 61,309 62,241 62,987
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on cervical cancer mortality also shows a continuous
decrease to a plateau of about 380 deaths annually (reduc-
tion of 64%).
A similar impact on the incidence of pre-cancerous
CIN1 and CIN2/3 was predicted, with a 64% decrease
with about 15,500 of CIN2/3 cases avoided annually and
a 59% decrease with about 4,800 cases of CIN1 pre-
vented annually in the long term. In a shorter term i.e.
after 20 years from the start of vaccination, a 48% and
50% reduction was observed in CIN2/3 and CIN1,____ No vaccination; - - - - vaccination strategy in 12-17 year old g
Figure 2 Effect of vaccination strategies on the incidence of cervical crespectively. Increasing vaccination coverage would lead
to earlier benefits (a 50% reduction in CIN1 being
observed 4 years earlier i.e. after 16 years from the start
of vaccination) and greater (87% and 81% reduction in
CIN2/3 and CIN1 in the long term) reductions.
The impact on genital warts is seen within a short
time because of their more rapid disease progression.
After less than five years, it is estimated that the inci-
dence of HPV6/11 related genital warts will be reduced
by 25% (Figure 3). After 15 years, quadrivalent HPV vac-
cination would avoid 57,780 cases of genital warts in
males and females (55% reduction). At steady state, geni-
tal wart cases among women and men (through herd ef-
fect) will be reduced by 69.9% and 48.2% respectively.
Economic impact of HPV6/11/16/18 vaccination
in Germany
Overall, the vaccination strategy would avoid 29% and
61% of the total discounted HPV6/11/16/18-related dis-
eases costs at 15 years and long term, respectively. Due
to the nature of the diseases, the discounted annual
HPV 6/11/16/18-costs avoided show their peak for
genital warts after 10 years, for CIN after 30 years and,
finally, for cervical cancer after 40 years. In the first five
years of vaccination, 96% of the total HPV-related dis-
eases costs avoided would be attributable to the preven-
tion of HPV6/11-related diseases, due to the generally
shorter latency period for these diseases. This relative
proportion would decrease to 44% after 50 years. Over
100 years, 57% of the total cumulated discounted costs
avoided would be linked to prevention of genital warts.irls;  _ ._ . _ increase vaccination coverage for 12-17 year old girls 
ancer.




















____ genital warts in females with no vaccination; - - - - direct effect of vaccination of girls on genital warts in females
– – – genital warts in males with no vaccination; _ . _ . _ indirect effect of vaccination of girls on genital warts in males 
Figure 3 Effect of quadrivalent HPV vaccination in girls aged 12 to 17 years on the incidence of genital warts in females and males.
Schobert et al. Health Economics Review 2012, 2:19 Page 7 of 10
http://www.healtheconomicsreview.com/content/2/1/19Cost-effectiveness and sensitivity analyses
The ICER for vaccination of 12–17 year-old girls in
Germany was estimated at 5,525€/QALY and 10,205€/LYG
(life-years gained) (Table 6), which is below the threshold
commonly used in the UK (£30,000/QALY) by the
National Institute for Health and Clinical Excellence
(NICE) in economic evaluations as the threshold ratio.
We used this threshold since in Germany, there is no
fixed threshold of ICER below which health technology
is considered as ‘good value for money’ [35].
The results were most sensitive to discount rates,
duration of vaccine protection and utility scores but
remained below the NICE threshold of £30,000/QALY
so that HPV vaccination in the German setting can be
considered to be cost-effective (Figure 4). Excluding the
protection against HPV 6/11 infections and diseases
increased the ICER to 10,296€/QALY. Increasing vac-
cine coverage for 12 to 17 year old girls in Germany as
described in sensitivity analyses only increased the ICER
to 5,807€/QALY. Variation in disease treatment costs
had a minor impact on the ICER (Figure 4).
Discussion
The results from this analysis show that the current HPV
vaccination programme of females ages 12 to 17 in
Germany is cost-effective with an ICER of 5,525€/QALY.
Excluding the vaccine effect on HPV6/11 diseases was con-
sidered, the ICER increased to 10,293€/QALY. While this
remains cost-effective using the NICE threshold, it empha-
sises the added value of protection against HPV6/11 dis-
eases. Increasing vaccine coverage in the recommended
population would lead to larger and earlier reductions with
only a small impact on the ICER (5,807€/QALY).At steady state, the model predicted that vaccinating girls
aged 12 to 17 could reduce the number of HPV 6/11/16/
18-related cervical cancers by 65% and genital warts among
women and men by 70% and 48% respectively. The impact
on HPV-related disease incidence and costs avoided was
found to occur relatively soon after initiating the vaccine
programme, with much of the early impact being due to
the prevention of HPV6/11-related genital warts. There is
consistent and growing evidence from several studies that
the effects predicted by this model are being observed in
the real world. In Australia, in 2009, 65% of Australian
females eligible for free vaccination (i.e. female Australian
residents aged between 12 and 26 years old) had been vac-
cinated [36]. A study comparing two 12-month periods in
2007–08 and 2010–11 showed a dramatic reduction in the
incidence of genital warts from 18.6% to 1.9% and 22.9% to
2.9% in under 21-year-old women and heterosexual men,
respectively, attending a sexual health centre in Melbourne
4 years following the start of vaccination implementation
[37]. The same trend was reported in another study of
patients attending eight sexual health services in different
states of Australia between January 2004 and December
2009 [36]. Since no other relevant health intervention was
implemented during this time and the incidence of other
sexually-transmitted diseases was unchanged the observed
effect is most likely to be attributable to the broad and
high vaccine coverage in young women. This is reinforced
by similar results reported in New Zealand [38] and
California.
Our model also predicts a reduction in cervical disease
outcomes, which has been reported in two studies, so
far. In a case–control study in New York, girls aged 11 to
21 who had received at least one HPV vaccination prior
Table 6 Cost-effectiveness of quadrivalent HPV vaccination in Germany
Costs (€) Δ Costs (€) QALYs Δ QALYs Δ Costs/Δ
QALYs
(€/QALY)
LYG Δ LYGs Δ Costs/Δ
LYG
(€/LYG)
Screening only 15,108,454 2,853,042 3,163,556
Base case 19,506,654 4,398,200 2,853,838 796 5,525 3,163,987 431 10,205
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tically significant lower risk of having an abnormal Pap
smear result (OR= 0.254; 95%CI: 0.093-0.698; p = 0.008)
[39]. Results from an ecological study suggest an early
effect from the HPV vaccination programme on cervical
abnormalities in Victoria, Australia [40]. They reported a
decrease in the incidence of high-grade cervical abnor-
malities of 0.38% (95%CI: 0.61-0.16) in girls under
18 years old less than three years after the introduction
of the quadrivalent HPV vaccination programme. This
decline was not observed for low-grade cervical abnor-
malities or in older age groups [40].
Our results are consistent with those predicted using a
static model for Germany which found an ICER of
10,530€/QALY for preventing cervical cancer and genital
warts [18], although the two analyses did not compare
the same vaccination cohort and the structures of the
models are different.
The limitations of this model have been described in
detail elsewhere but here we will briefly discuss some
potential limitations specific to this analysis [21]. Firstly,
as no German-specific data on sexual behaviour were
available, we used data from the UK. The impact this
may have on the predictions is unknown [26]. Secondly,
we used a simple calibration approach, similarly to what
was done in the Norwegian and UK adaptation, and we
calibrated the model with global incidence but not withFigure 4 Tornado diagram summarising the results of the sensitivityage-specific data [19,20]. It is clear that the calibration
process is one of the critical steps of the model adapta-
tion. The model was initially developed for the US and
followed an extensive calibration approach, where age-
specific data were considered. As we did not modify any
natural history parameters, but only a few parameters
such as the proportion of women who do not screen
regularly, we probably did not changed the peak of the
incidence curves of cervical cancer incidence and mor-
tality, and we think that focusing on global incidence
rates was an acceptable approach. Thirdly, we consid-
ered only direct costs; in future analyses, indirect costs,
such as productivity loss, should be included so that the
results would be closer to reality. Another limitation
concerns the estimates for the health utilities, which
were taken from a study performed in the US. However,
as far as we are aware, there are no such estimates avail-
able for Germany or for any other European country.
We also assumed 100% vaccine adherence with each of
the three vaccine doses without making allowance for a
drop-out rate after one or two doses which may not
reflect the reality, but there is no efficacy data available for
less than three doses. Furthermore, we did not consider
any potential adverse effects of the vaccine. Although vac-
cination with the quadrivalent vaccine is generally well tol-
erated so we would expect that including them into the
model would have only a minor impact on the ICER.analyses.
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impact on non-vaccine types in our model, as the model
did not include HPV types non-included in the vaccines.
There is uncertainty about the accuracy of the observed
cross-protection as it is not always easy to determine the
causal HPV type in a lesion [41]. It is also unknown
whether cross-protective efficacy will be long lasting
[41], recent data suggest that cross-protective effects are
short lived and therefore of limited value. The results from
a UK modelling analysis comparing the cost-effectiveness
of the quadrivalent and bivalent vaccines, showed that
additional cross-protection only had a minor contribu-
tion in terms of economic benefits (i.e. QALYs gained
and costs prevented), especially if compared with benefits
for genital warts [41]. Therefore, we could assume that
inclusion of vaccine efficacy against non-vaccine types
would only have a limited impact on our results.
Another limitation is that we did not perform prob-
abilistic sensitivity analyses. Nevertheless, results from the
sensitivity analysis confirm the findings of many other
models and showed that results were sensitive to assump-
tions about the duration of protection and discount rates.
Lastly, only cervical diseases and genital warts were
included in the present model. However, HPV has been
found in significant numbers of vulvar, vaginal and anal
cancers and the quadrivalent vaccine has demonstrated
high efficacy in preventing these lesion [6,17,42]. HPV is
also found in a proportion of head and neck squamous
cell cancers [7]. Recently two reviews have concluded
that the available data are consistent with the hypothesis
that HPV does have a causal role in head and neck cancer
[43,44]. There are no clinical efficacy data for head and
neck cancer because there are no precursor lesions for
head and neck cancer and recurrent respiratory papillo-
matosis (RRP) is very rare. However, it is reasonable to
think that the quadrivalent HPV vaccine could prevent
these diseases. If these diseases were to be included in the
model, the protection by HPV vaccination would be
expected to be greater, which would give a lower ICER.
HPV-related non-cervical cancers were included in a
recent UK modelling study that predicted that, in addition
to a median of 700 to 1000 cervical cancers, in the long-
term, HPV vaccination could prevent between 620 and
950 cases of these cancers annually in the UK [41]. Future
cost-effectiveness analyses for HPV vaccination should,
therefore, include these diseases to provide a more accur-
ate prediction of the cost-effectiveness of HPV vaccin-
ation. In light of the recent clinical trial results showing
the efficacy of the quadrivalent HPV for the prevention of
genital warts and precancerous anal lesions in males it
will also be of importance for decision makers to assess
the potential impact of vaccination of females and males
on female and male HPV-related diseases [16,17]. Some
countries, e.g. Australia, Canada and the US have recentlyrecommended the inclusion of boys in their vaccination
programmes.
Conclusions
The results from this model show that the current
quadrivalent HPV vaccination programme, in addition
to the screening programme in Germany, will provide
public health benefits by substantially reducing the inci-
dence of cervical cancer, CIN and genital warts. The vac-
cination strategies evaluated in this study were all found
to be cost-effective. Future modelling analyses should
include more HPV-related diseases.
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